LNLuis Fernando Ng-Sueng

Luis Fernando Ng-Sueng

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Luis Fernando Ng-Sueng has a total of 37 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Efficacy and harms of convalescent plasma for treatment of hospitalized COVID-19 patients: a systematic review and meta-analysis

    by Alejandro Piscoya, Luis Fernando Ng-Sueng, Angela Parra del Riego, Renato Cerna-Viacava, Vinay Pasupuleti, Priyaleela Thota, Yuani M Roman, Adrian V Hernandez

    Introduction: We systematically reviewed benefits and harms of convalescent plasma (CP) in hospitalized COVID-19 patients.Material and methods: Randomized controlled trials (RCTs) and observational studies assessing CP effects on hospitalized, adult COVID-19 patients were searched until November 24, 2020. We assessed risk of bias (RoB) using Cochrane RoB 2.0 and ROBINS-I tools. Inverse variance random effect meta-analyses were performed. Quality of evidence was evaluated using GRADE methodology. Primary outcomes were all-cause mortality, clinical improvement, and adverse events.Results: Five RCTs (n = 1067) and 6 cohorts (n = 881) were included. Three and 1 RCTs had some concerns and high RoB, respectively; and there was serious RoB in all cohorts. Convalescent plasma did not reduce all-cause mortality in RCTs of severe (RR = 0.60, 95% CI: 0.33–1.10) or moderate (RR = 0.60, 95% CI: 0.09–3.86) COVID-19 vs. standard of care (SOC); CP reduced all-cause mortality vs. SOC in cohorts (RR = 0.66, 95% CI: 0.49–0.91). Convalescent plasma did not reduce invasive ventilation vs. SOC in moderate disease (RR = 0.85, 95% CI: 0.47–1.55). In comparison to placebo + SOC, CP did not affect all-cause mortality (RR = 0.75, 95% CI: 0.48–1.16) or clinical improvement (HR = 1.07, 95% CI: 0.82–1.40) in severe patients. Adverse and serious adverse events were scarce, similar between CP and controls. Quality of evidence was low or very low for most outcomes.Conclusions: In comparison to SOC or placebo + SOC, CP did not reduce all-cause mortality in RCTs of hospitalized COVID-19 patients. Convalescent plasma did not have an effect on other clinical or safety outcomes. Until now there is no good quality evidence to recommend CP for hospitalized COVID-19 patients.


  • Open Access

    Efficacy and harms of remdesivir for the treatment of COVID-19: A systematic review and meta-analysis

    by Alejandro Piscoya, Luis F. Ng-Sueng, Angela Parra del Riego, Renato Cerna-Viacava, Vinay Pasupuleti, Yuani M. Roman, Priyaleela Thota, C. Michael White, Adrian V. Hernandez

    Background: Efficacy and safety of treatments for hospitalized COVID-19 are uncertain. We systematically reviewed efficacy and safety of remdesivir for the treatment of COVID-19. Methods: Studies evaluating remdesivir in adults with hospitalized COVID-19 were searched in several engines until August 21, 2020. Primary outcomes included all-cause mortality, clinical improvement or recovery, need for invasive ventilation, and serious adverse events (SAEs). Inverse variance random effects meta-analyses were performed. Results: We included four randomized controlled trials (RCTs) (n = 2296) [two vs. placebo (n = 1299) and two comparing 5-day vs. 10-day regimens (n = 997)], and two case series (n = 88). Studies used intravenous remdesivir 200mg the first day and 100mg for four or nine more days. One RCT (n = 236) was stopped early due to AEs; the other three RCTs reported outcomes between 11 and 15 days. Time to recovery was decreased by 4 days with remdesivir vs. placebo in one RCT (n = 1063), and by 0.8 days with 5-days vs. 10-days of therapy in another RCT (n = 397). Clinical improvement was better for 5-days regimen vs. standard of care in one RCT (n = 600). Remdesivir did not decrease all-cause mortality (RR 0.71, 95%CI 0.39 to 1.28, I2 = 43%) and need for invasive ventilation (RR 0.57, 95%CI 0.23 to 1.42, I2 = 60%) vs. placebo at 14 days but had fewer SAEs; 5-day decreased need for invasive ventilation and SAEs vs. 10-day in one RCT (n = 397). No differences in all-cause mortality or SAEs were seen among 5-day, 10-day and standard of care. There were some concerns of bias to high risk of bias in RCTs. Heterogeneity between studies could be due to different severities of disease, days of therapy before outcome determination, and how ordinal data was analyzed. Conclusions: There is paucity of adequately powered and fully reported RCTs evaluating effects of remdesivir in hospitalized COVID-19 patients. Until stronger evidence emerges, we cannot conclude that remdesivir is efficacious for treating COVID-19.


  • Open Access

    Efficacy and harms of remdesivir for the treatment of COVID-19: a systematic review and meta-analysis

    by Alejandro Piscoya, Luis Fernando Ng-Sueng, Angela Parra del Riego, Renato Cerna-Viacava, Vinay Pasupuleti, Yuani M. Roman, Priyaleela Thota, C. Michael White, Adrian V. Hernandez

    Background: We evaluated the efficacy and safety of remdesivir for the treatment of COVID-19. Methods: Systematic review in five engines, pre-print webpages and RCT registries until May 22, 2020 for randomized controlled trials (RCTs) and observational studies evaluating remdesivir on confirmed, COVID-19 adults with pneumonia and/or respiratory insufficiency. Primary outcomes were all-cause mortality, clinical improvement or recovery, need for invasive ventilation, and serious adverse events (SAE). Secondary outcomes included length of hospital stay, progression of pneumonia, and adverse events (AE). Inverse variance random effects meta-analyses were performed. Results: Two placebo-controlled RCTs (n=1300) and two case series (n=88) were included. All studies used remdesivir 200mg IV the first day and 100mg IV for 9 more days, and followed up until 28 days. Wang et al. RCT was stopped early due to AEs; ACTT-1 was preliminary reported at 15-day follow up. Time to clinical improvement was not decreased in Wang et al. RCT, but median time to recovery was decreased by 4 days in ACTT-1. Remdesivir did not decrease all-cause mortality (RR 0.71, 95%CI 0.39 to 1.28) and need for invasive ventilation at 14 days (RR 0.57, 95%CI 0.23 to 1.42), but had fewer SAEs (RR 0.77, 95%CI 0.63 to 0.94). AEs were similar between remdesivir and placebo arms. Risk of bias ranged from some concerns to high risk in RCTs. Interpretation: There is paucity of adequately powered and fully reported RCTs evaluating effects of remdesivir in adult, hospitalized COVID-19 patients. Remdesivir should not be recommended for the treatment of severe COVID-19.


  • Open Access

    Gender Associated with the Intention to Choose a Medical Specialty in Medical Students: A Cross-Sectional Study in 11 Countries in Latin America

    by Luis Fernando Ng-Sueng, Iván Vargas-Matos, Percy Mayta-Tristán, Reneé Pereyra-Elías, Juan José Montenegro-Idrogo, Fiorella Inga-Berrospi, Felix Ancalli, Francisco Bonilla-Escobar, Cristian Diaz-Velez, Erick Gutierrez-Quezada, et al.

    The selection of a medical specialty has been associated with multiple factors, such as personal preferences, academic exposure, motivational factors and sociodemographic factors, such as gender. The number of women in the medical field has increased in recent years. In Latin America, we have not found any studies that explore this relationship. To determine whether there is an association between gender and the intention to choose a medical specialty in medical students from 11 countries in Latin America. Secondary analysis of the Collaborative Working Group for the Research of Human Resources for Health (Red-LIRHUS) data; a multi-country project of students in their first year and fifth year of study, from 63 medical schools in 11 Latin American countries. All students who referred intention to choose a certain medical specialty were considered as participants. Of the 11073 surveyed students, 9235 indicated the name of a specific specialty. The specialties chosen most often in the fifth year were General Surgery (13.0%), Pediatrics (11.0%), Internal Medicine (10.3%) and Obstetrics/Gynecology (9.0%). For women, the top choices were Pediatrics (15.8%), Obstetrics/Gynecology (11.0%), Cardiology (8.7%), General Surgery (8.6%), and Oncology (6.4%). In the adjusted analysis, the female gender was associated with the choice of Obstetrics/Gynecology (RP: 2.75; IC95%: 2.24–3.39); Pediatric Surgery (RP: 2.19; IC95%: 1.19–4.00), Dermatology (RP: 1.91; IC95%:1.24–2.93), Pediatrics (RP: 1.83; IC95%: 1.56–2.17), and Oncology (RP: 1.37; IC95%: 1.10–1.71). There is an association between the female gender and the intention to choose Obstetrics/Gynecology, Pediatrics, Pediatric Surgery, Dermatology, and Oncology. We recommend conducting studies that consider other factors that can influence the choice of a medical specialty.


    • 24 September 2015
      • Vol. 35  (3) , 129-225

    [Overlap of irritable bowel syndrome and functional dyspepsia based on Rome III criteria in medical students from a private university in Lima, Peru].

    by Iván Vargas-Matos, Luis Fernando Ng-Sueng, Joel Flores-Arriaga, Santiago Beltrán-Flores, Mauricio Lema-Correa, Alejandro Piscoya, Percy Mayta-Tristán

    To determine the prevalence of irritable bowel syndrome and functional dyspepsia in medical students from a private university in Lima, Peru. Furthermore, to determine the associated factors with these diseases. Observational descriptive and retrospective cross sectional study. Medical students from a private university in Lima were surveyed using a Rome III questionnaire for functional disorders and the STEPwise auto survey for defining the variables of alcohol and tobacco. For data analysis the Stata 11.0 program was used. Of the 608 students, 543 answered the questionnaire. The prevalence of Irritable Bowel Syndrome was 12.4%, 16.9% of dyspepsia, and of both diseases simultaneously, a prevalence of 7.1% was found. Alcohol consumption in the total population was 89.4% and 29.0% of tobacco. Association between both disorders was found (OR 10.47, 95% CI 5.08 to 21.55; p < 0.001), dyspepsia was associated with sex (OR: 0.16, 95% CI 0.07 to 0.36 p < 0.001), with alcohol consumption (OR: 5.22, 95% CI 23.99 1,13- p = 0.034) and with irritable bowel syndrome (OR: 9.88, 95% CI 4.78 to 20.46 p <0.001). Both conditions together were associated with sex (OR: 0.20, 95% CI from 0.06 to 0.60 p = 0.004) and daily consumption of tobacco (OR: 3.23, 95% CI 1.17 to 8.89 p = 0.023). A prevalence of 12.4% of Irritable Bowel Syndrome and 16.9% of dyspepsia was determined. An overlap of 7.1% of these diseases was reported.


  • Open Access

    Publicación de los trabajos presentados a los congresos científicos de estudiantes de medicina, Perú 2002-2009: características y factores asociados

    by Luis Miguel Toro-Polo, Reneé Pereyra-Elías, Ayar Nizama-Vía, Luis Fernando Ng-Sueng, Eduardo Vélez-Segovia, Edén Galán-Rodas, Percy Mayta-Tristán

    Objetivos. Determinar la proporción de publicación de los resúmenes presentados a los congresos científicos nacionales de estudiantes de medicina de Perú entre los años 2002 y 2009 y sus factores asociados. Materiales y métodos. Se realizó una cohorte retrospectiva, se evaluó las características de todos los resúmenes presentados y se determinó si habían sido publicados en revistas científicas utilizando una estrategia de búsqueda validada con Google Académico. Se calculó los riesgos relativos (RR), crudos y ajustados mediante la regresión de Poisson con varianza robusta para evaluar asociación con los factores analizados. Resultados. Se analizó 532 resúmenes; 52 (9,8%) fueron publicados en revistas científicas luego de su participación en el congreso; en todos los casos fue en revistas peruanas y en español. La principal revista donde se publicaron fue (CIMEL) (13/52). La mediana del tiempo de publicación fue de 13 meses (rango: 0-75). El que un alumno de la Universidad Nacional Mayor de San Marcos (RR: 5,18; IC95%:2,3-11,6) sea autor del resumen y que el resumen sea de autoría colaborativa entre alumnos de dos universidades (RR: 3,64; IC95%:1,1-11,7) son factores asociados en el análisis multivariado. Conclusiones. La proporción de publicación de resúmenes presentados a los congresos científicos nacionales de estudiantes de medicina de Perú es baja. Se deben implementar nuevas medidas y reforzar las existentes para incentivar una mayor publicación de los trabajos presentados.

  • Open Access

    Publicación de los trabajos presentados a los congresos científicos de estudiantes de medicina, Perú 2002-2009: características y factores asociados.

    by Miguel Toro-Polo, Reneé Pereyra-Elías, Ayar Nizama-Vía, Luis Fernando Ng-Sueng, Eduardo Vélez-Segovia, Edén Galán-Rodas, Percy Mayta-Tristán

    To determine the publication rate of abstracts submitted at the national scientific meetings of medical students in Peru between 2002 and 2009, and associated factors. A retrospective cohort was performed; the characteristics of overall abstract submitted were assessed. In addition, whether they were published in scientific journals was determined by way of a search strategy validated using Google Scholar. Crude and adjusted relative risks (RR) were calculated using Poisson regression with robust variance to assess association with the analyzed factors. 532 abstracts were analyzed, 52 (9.8%) of which were published in scientific journals after their presentation at a scientific meeting. All of them were published in Peruvian journals written in Spanish. The most important journal in which they were published was Ciencia e Investigación Médica Estudiantil Latinoamericana (CIMEL) (13/52). The median of publication time was 13 months (range: 0-75). The fact that a student from the Universidad Nacional Mayor de San Marcos (RR: 5.18; CI95%:2.3-11.6) is the author of the abstract and that the abstract was collaboratively written by students from two universities (RR: 3.64; CI95%:1.1-11.7) are associated factors in the multivariate analysis. The publication rate of abstract submitted at national scientific meetings of medical students in Peru is low. New strategies should be taken, and the existing ones should be reinforced in order to increase the publication rate of the abstract submitted.


    • 13 August 2011
      • Vol. 31  (2) , 124-32

    [Low publication of the papers presented at the Congresses of Gastroenterology Society of Peru 1998-2008].

    by Reneé Pereyra-Elías, Luis Fernando Ng-Sueng, Luis Miguel Toro-Polo, Ayar Nizama-Vía, Alejandro Piscoya, Percy Mayta-Tristán

    To determine the proportion of abstracts presented at the Congreso Peruano de Gastroenterología (the major Peruvian gastroenterological scientific meeting), that had been published in scientific journals, the date of publication and its associated factors. Longitudinal retrospective and analytic study; the publicationrate of all the abstracts presented in the biennial Congreso Peruano de Gastroenterología between 1998 and 2008 was assessed. Google Scholar engine was used. The searching strategy performed included: ("Study location" AND "population studied" AND "main outcome") AND (autor:First OR autor:Second OR autor:Last). Logistic regression was used, considering p<0.05 statistically significant. Publication rate was 8.2% (34/217), statistically significant differences were found among meeting years (p<0.001). There were also differences between study design, objectives (more in analytic studies) and measurement (more in longitudinal studies (p<0.001). 82.4% were published in the Revista de Gastroenterología del Perú. The median time for publication was 10.8±10.4 months; this variable and the meeting year, study type, journal of publication or accordance between the abstract and publication characteristic showed no statistical differences. The mean authors' number was 5.02±2.4; analytic studies have less authors than the descriptive ones (3.6 vs 6.1; p=0.012). The Congreso Peruano de Gastroenterología presents a low publication rate of the abstracts presented, which can be used as a quality indicator of the abstracts and the reviewing process.